Full Technology Summary

OLED technology is garnering more acceptance among end users as it is thinner, brighter, lightweight, power efficient and offers higher contrast compared to LCDs. OLEDs offer wide viewing angles, faster response times, higher contrast ratios and more saturated colors to enhance viewing experience of end users. OLED is one of the most promising display and lighting technologies that has the capability of offering power efficiency lighting and is superior compared to the fluorescent tubes and incandescent bulbs. OLED technology also enables end user to create flexible display and lighting panels.

According to a new market research report "OLED Market by Display Application (Type - AMOLED & PMOLED, Panel-Size - Small, Medium & Large, Product - Smartphones & Others, Geography), Lighting Application (Type - Traditional & Flexible, End-User, Geography), & Geography - Global Forecast to 2020", the total OLED market is expected to reach $43.92 billion by 2020, at a CAGR of 16% between 2014 and 2020.

Due to the high fabrication cost of OLEDs as well as expensive materials needed to manufacture OLED devices, the best application of OLEDs at this time is in decorative luminaires, light-art installations, high-end feature spaces and architectural applications that exploit OLEDs’ unique properties.

Invention:

Scientists at the University of Saskatchewan have discovered a plant-source compound as a single molecule white light emitter and a technology to use this material to produce OLED devices. This game-changing technology has the potential of significantly reducing the costs of OLED devices and make OLED technology affordable for the main display and lighting industry. Key features of this invention include:

•       It works! A prototype has been developed;

•       Low cost. The cost of this material is only about 1/10 of other white light emitting materials such as FPt;

•       Secured supply: The material is plant-sourced which can be easily produced in bulk quantities;

•       Durable: The material has a very stable structure and is durable at high temperatures

Below is the key characterization of the OLED device prototype:

Opportunity:

We are looking for industry partners to maximize the commercialization potential of this technology by licensing as well as industry-engaged collaborative research.

For more information, please contact:

Frank Su, PhD, MBA, MBT

Technology Transfer Manager

306-966-1727

Frank.su@usask.ca

Download full technology summary

Benefits of flax lignans:

Lignans are naturally occurring biologically active polyphenolic compounds present in flaxseed. The major lignan in flaxseed is SDG (Secoisolariciresinol diglucoside) and flaxseed is the richest known source of this compound (Fig.1). Cell models, animal studies, epidemiological studies, and randomized human clinical trials have all demonstrated significant potential for flaxseed lignan supplementation in management of or risk reduction for a number of chronic diseases including cancer, heart disease, BPH, hypertension, and inflammatory bowel disease.

History of Industry Engagement:

In 2007 Archer Daniels Midland (ADM) began marketing a flaxseed lignan enriched complex (38% SDG) called BeneFlax® with both FDA and Health Canada approval. Later, ADM stopped production of BeneFlax® to focus on soy isoflavanoids. However there has been a growing body of science to support the value of lignan supplementation in management of chronic diseases. Bioactive enriched products like BeneFlax® are likely to show meaningful therapeutic or chemopreventative properties.

Commercial Opportunity:

Archer Daniels Midland has expressed a willingness to work with any company interested in resuming production of BeneFlax®. We are seeking the interest of investors to revive the technology and resume production of BeneFlax® or a BeneFlax® like product. We believe that the market is now more receptive to this product than it was 8 years ago and the new science including the current studies at the University of Saskatchewan supports an expanded range of uses for BeneFlax® including as a sole therapeutic, an adjuvant therapy, or chemopreventative for chronic disease such as risk factors for cardiovascular disease (e.g. hypercholesterolemia, hypertension) and inflammatory conditions of the gastrointestinal tract, such as inflammatory bowel disease.

Collaborators:

Dr. Alcorn has built a strong collaborative network of researchers and clinician researchers including Dr. Ed Krol (Pharmacy and Nutrition, Dr. Phil Chilibeck (Kinesiology), Dr. Susan Whiting (Pharmacy and Nutrition), Dr. Sharyle Fowler (Medicine), and Dr. Thomas Hadjistavropoulos (U. of Regina), as well as with one of the original inventors of the technology for BeneFlax, Dr. Alister Muir, to create an integrated package of safety, efficacy, and mechanism of action data for the lignans of flaxseed.

Pre clinical Data:

In Dr. Alcorn’s laboratory, animal model studies demonstrate clear anticholesterolemic effects and in vitro analyses may have identified lignan mode of action (a novel mechanism) in the hypercholesterolemic effect of lignans (results pending). Furthermore, in vitro analyses are demonstrating important effects in inflammatory conditions of the gastrointestinal tract. (Fig 2) As well, in in vitro evaluations we have we demonstrated synergism between the lignans and important chemotherapeutic agents used in treatment of breast or prostate cancer (Table 1).

Clinical Data:

Recently completed Phase IIa human clinical trials in healthy and frail older adults indicate good safety and tolerability of BeneFlax®. Current human clinical trials are underway to examine efficacy of BeneFlax® oral supplementation in patients with 1) mild-to-moderate ulcerative colitis and 2) elderly patients with high normal to stage I hypertension. Furthermore, a validated pharmaceutical analytical method has allowed for important pharmacokinetic (PK) characterizations of the flaxseed lignans (e.g. intestinal permeability in Caco-2, phase II metabolism in intestinal and hepatic microsomes, cytochrome P450 inhibition potential (DDI potential), PK of individual flaxseed lignans in animal models, PK of single oral dose and multiple oral dose administration of BeneFlax® in healthy adults (Fig. 3)). The combination of our biomedical studies on safety, efficacy, and mechanism of action, and clinical trials to confirm the biomedical studies, has compiled important information to begin to establish a scientific basis for possible health claims for the flaxseed lignans.